JADE101 Drives 70% IgA Reductions with 12-Week Dosing and Strong Tolerability
JBIO•JADE101 achieved approximately 70% IgA reductions from baseline sustained at 12 weeks after a single 700 mg subcutaneous dose in healthy volunteers, outperforming first-generation anti-APRIL and dual APRIL/BAFF therapies. Simulations project over 70% IgA reduction at steady state with 350 mg administered every 12 weeks, and JADE101 was well tolerated across evaluated doses.
1. Interim Phase 1 Efficacy Results
JADE101 reduced IgA by ~70% at 12 weeks post single 700 mg subcutaneous dose in healthy volunteers, surpassing reductions seen with first-generation anti-APRIL and dual APRIL/BAFF agents. Simulations indicate that 350 mg Q12W dosing could sustain >70% reductions at steady state, supporting a dosing schedule of only four injections per year.
2. Safety and Pharmacokinetics
Single subcutaneous doses up to 1,400 mg were well tolerated, with no serious adverse events or hypogammaglobulinemia reported. JADE101 demonstrated a half-life approximately 8.7-fold longer than povetacicept and 2.6-fold longer than sibeprenlimab, with no apparent impact from anti-drug antibodies.
3. Clinical Development Outlook
An open-label Phase 2 trial (JUNIPER) is enrolling ~30 IgAN patients with a 700 mg induction dose followed by 350 mg maintenance every 8 or 12 weeks. Interim Phase 2 data are anticipated in 2027, and a Phase 3 registrational trial is planned for the first half of 2027.
